1. Home
  2. PRME vs FSTR Comparison

PRME vs FSTR Comparison

Compare PRME & FSTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Prime Medicine Inc.

PRME

Prime Medicine Inc.

SELL

Current Price

$4.23

Market Cap

526.0M

Sector

Health Care

ML Signal

SELL

Logo L.B. Foster Company

FSTR

L.B. Foster Company

SELL

Current Price

$41.77

Market Cap

442.3M

Sector

Industrials

ML Signal

SELL

Company Overview

Basic Information
Metric
PRME
FSTR
Founded
2019
1902
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Metal Fabrications
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
526.0M
442.3M
IPO Year
2022
1995

Fundamental Metrics

Financial Performance
Metric
PRME
FSTR
Price
$4.23
$41.77
Analyst Decision
Buy
Analyst Count
13
0
Target Price
$7.03
★ $45.50
AVG Volume (30 Days)
★ 5.5M
32.8K
Earning Date
11-12-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 18.18
N/A
EPS
N/A
★ 1.07
Revenue
$4,632,000.00
★ $540,009,000.00
Revenue This Year
$18.58
$6.53
Revenue Next Year
$23.34
$4.30
P/E Ratio
★ N/A
$39.63
Revenue Growth
★ 55.28
1.74
52 Week Low
$2.67
$25.66
52 Week High
$5.91
$45.81

Technical Indicators

Market Signals
Indicator
PRME
FSTR
Relative Strength Index (RSI) 51.32 63.80
Support Level $2.94 $40.01
Resistance Level $4.80 $43.03
Average True Range (ATR) 0.53 1.47
MACD -0.08 0.52
Stochastic Oscillator 22.25 78.80

Price Performance

Historical Comparison
PRME
FSTR

About PRME Prime Medicine Inc.

Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.

About FSTR L.B. Foster Company

L.B. Foster Co is a technology solutions provider of products and services for the rail and infrastructure markets. The company has two reporting segments: Rail, Technologies, and Services (Rail); and Infrastructure Solutions (Infrastructure). Maximum revenue is generated from the Rail segment, which is comprised of several manufacturing and distribution businesses that provide products and services for freight and passenger railroads and industrial companies throughout the world. The Infrastructure segment offers engineered precast concrete solutions, as well as fabricated bridge, protective pipe coating, and pipe threading offerings across North America. Geographically, the company generates maximum revenue from the United States, followed by Canada, the UK, and other markets.

Share on Social Networks: